⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385639 | 1.00 | — | — | |
| SCHEMBL13816904 | 1.00 | — | — | |
| SCHEMBL22639535 | 1.00 | — | — | |
| SCHEMBL24434609 | 1.00 | — | — | |
| SCHEMBL7749478 | 0.83 | — | — | |
| SCHEMBL16385695 | 0.83 | — | — | |
| SCHEMBL12641505 | 0.81 | — | — | |
| SCHEMBL18927544 | 0.81 | — | — | |
| SCHEMBL16385638 | 0.81 | — | — | |
| Methyl Alcohol SCHEMBL28201259 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025016906-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016909-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| CN-118738558-A | Secondary battery electrolyte and application thereof | 蓝固(常州)新能源有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2017049177-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-2507669-B1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, FILM FORMED USING THE COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORP (JP) | 2015-01-07 | — | — | EP | disclosed |
| WO-2012026621-A1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN THEREWITH | FUJIFILM CORPORATION (JP) | 2012-03-01 | — | — | WO | disclosed |
| US-20090035702-A1 | PROCESS FOR PRODUCING COMPOUND HAVING ACID-LABILE GROUP | KYOWA HAKKO CHEMICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20060177763-A1 | Method for producing compound having acid-labile group | KYOWA HAKKO CHEMICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1661918-A1 | METHOD FOR PRODUCING COMPOUND HAVING ACID-LABILE GROUP | Kyowa Hakko Chemical Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6331650-B1 | Method for manufacturing aminoalcohol | KURARAY CO., LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-1074541-A1 | Method for manufacturing aminoalcohol | Kuraray Co., Ltd., Kurashiki Plant (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-0239195-B1 | LIQUID DETERGENT COMPOSITIONS | UNILEVER PLC (GB) | 1989-07-26 | — | — | EP | disclosed |
| EP-0239195-A1 | Liquid detergent compositions | UNILEVER PLC (GB) | 1987-09-30 | — | — | EP | disclosed |